Shares of micro-cap biotech vTv Therapeutics Inc VTVT were advancing to their highest level since October 2018 Monday following a clinical readout from the company.
Success In Phase 2 For VTV Therapeutics
High Point, North Carolina-based vTv said part two of the Phase 2 Simplici-T1 trial achieved the primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis, at week 12.
The study is evaluating TTP399 as an oral adjunctive therapy to insulin in adults with Type 1 diabetes.
TTP399 is a liver-selective glucokinase activator taken once a day.
The study, which evaluated 85 type 1 diabetes patients on optimized insulin therapy, studied the efficacy and safety of the experimental drug at 800mg dose relative to placebo.
TTP399 was well-tolerated, with similar incidences of treatment-emergent adverse events overall and by system organ class in both treatment groups, the company said.
Big Win For Type 1 Diabetes Care
"I am very pleased that part 2 of the study confirmed the positive results and effects we saw in part 1. A once-a-day pill that reduces HbA1c and improves time in range with continuous glucose monitoring, without increasing hypoglycemia or any signal for adverse events, is a big win for the future care of type 1 diabetes," Dr. John Buse, a clinical diabetologist, said in a press release.
About 1.5 million people in the U.S. live with type 1 diabetes, requiring round-the-clock monitoring and management to avoid life-threatening complications, according to vTv Therapeutics.
"Consistent with FDA guidance, a 0.3% improvement in HbA1c is considered clinically meaningful, and coupled with the well-controlled population of patients and favorable safety data from our clinical trials to date, this provides a strong basis for moving this potential first-in-class program forward," CEO Steve Holcombe said in a statement.
The company said it plans to engage with the FDA as soon as possible to plan an efficient development pathway. It expects to initiate a registrational trial this year.
At last check, vTv shares were skyrocketing 56.95% to $3.30 on volume significantly above their average.
Related Links:
The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight
13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
